Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | SVP & Pres, Neuromodulation | February 28, 2022 | March 02, 2022 |
| Rani Therapeutics Holdings, Inc.RANI · Entity 6642 | Director | May 28, 2025 | May 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date February 28, 2022 · Filed March 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 177,258 |
Ending reported balance
After 2022-02-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-02-28 · Exercise / conversion · Acquired 1,630 · Balance 177,822 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 2 · 2022-02-28 · Tax withholding · Disposed 564 · Balance 177,258 |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Expires 2022-02-28 | Direct | 0 |
Reported balance
After 2022-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-02-28 · Exercise / conversion · Disposed 1,630 · Balance 0 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
Rani Therapeutics Holdings, Inc.
Report date May 28, 2025 · Filed May 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.62 · Expires 2035-05-27 | Direct | 50,000 |
Reported balance
After 2025-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-28 · Grant · Acquired 50,000 · Balance 50,000 F1: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2019 Filed Jan 16, 2019 21:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 3,038 | $35.46 | $107,727.48 |
DisclosureSEC source: 0001225208-19-000883 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,168 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 21:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,038 | $7.41 | $22,511.58 |
DisclosureSEC source: 0001225208-19-000883 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 10,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000440 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,750 shares Expires 2018-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. F1 · derivative.exercise_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. F1 · derivative.expiration_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 3,933 | $35.34 | $138,992.22 |
DisclosureSEC source: 0001225208-19-000440 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,168 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 10,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000440 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 21:25 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,458 | $0.00 Strike: $8.30 | $0.00 |
DisclosureSEC source: 0001225208-18-015657 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,458 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of common stock vesting in four equal annual installments beginning on February 24, 2010, the first anniversary of the date of grant. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 21:25 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 23,458 | $37.28 | $874,446.21 |
DisclosureSEC source: 0001225208-18-015657 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,351 F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $37.27 to $37.30, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 21:25 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 23,458 | $8.30 | $194,701.40 |
DisclosureSEC source: 0001225208-18-015657 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004947 · doc4.xml · derivative · entry 5 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,517 Underlying: Common Stock · 1,629 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 3,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004947 · doc4.xml · derivative · entry 4 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,383 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,486 | $27.26 | $67,768.36 |
DisclosureSEC source: 0001225208-18-004947 · doc4.xml · nonDerivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,363 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004947 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004947 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2018 Filed Feb 26, 2018 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004203 · doc4.xml · derivative · entry 6 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,676 Underlying: Common Stock · 2,676 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2018 Filed Feb 26, 2018 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,327 | $27.20 | $36,094.40 |
DisclosureSEC source: 0001225208-18-004203 · doc4.xml · nonDerivative · entry 4 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,837 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2018 Filed Feb 26, 2018 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004203 · doc4.xml · nonDerivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004203 · doc4.xml · derivative · entry 5 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,679 Underlying: Common Stock · 1,839 shares Expires 2020-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 803 | $27.20 | $21,841.60 |
DisclosureSEC source: 0001225208-18-004203 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,488 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004203 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004009 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,649 Underlying: Common Stock · 1,883 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 652 | $26.48 | $17,264.96 |
DisclosureSEC source: 0001225208-18-004009 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,452 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004009 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 25,027 | $0.00 Strike: $27.09 | $0.00 |
DisclosureSEC source: 0001225208-18-003399 · doc4.xml · derivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,027 Underlying: Common Stock · 25,027 shares Expires 2028-02-15 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 8,305 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003399 · doc4.xml · derivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,305 Underlying: Common Stock · 8,305 shares Expires 2023-02-15 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 7,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-002897 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,950 Underlying: Common Stock · 7,950 shares Expires 2019-12-31 F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. F4 · derivative.exercise_date: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. F4 · derivative.expiration_date: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. F4 · balance_after: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 6,360 | $26.18 | $166,504.80 |
DisclosureSEC source: 0001225208-18-002897 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,221 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 18,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-002897 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,581 F1 · shares: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person was based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2017 and was subject to the completion of the concurrent three-year individual service period. On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:38 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,568 | $0.00 Strike: $12.52 | $0.00 |
DisclosureSEC source: 0001225208-18-002503 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,568 shares Expires 2018-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase 25,568 shares of common stock vesting in four annual increments beginning on February 12, 2009, the first anniversary of the grant. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:38 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 15,568 | $25.38 | $395,112.73 |
DisclosureSEC source: 0001225208-18-002503 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,189 F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.37 to $25.392, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:38 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 15,568 | $12.52 | $194,911.36 |
DisclosureSEC source: 0001225208-18-002503 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 23:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 10,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-000453 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,005 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. F1 · derivative.exercise_date: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. F1 · derivative.expiration_date: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 23:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 4,049 | $24.79 | $100,374.71 |
DisclosureSEC source: 0001225208-18-000453 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,189 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 23:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 10,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-000453 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001225208-17-014467 · doc4.xml · derivative · entry 12 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,035 Underlying: Common Stock · 10,000 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001225208-17-014467 · doc4.xml · derivative · entry 11 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,231 Underlying: Common Stock · 20,000 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase 48,231 shares of common stock vesting in four annual increments beginning on February 16, 2011, the first anniversary of the grant. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 30,000 | $27.45 | $823,539.00 |
DisclosureSEC source: 0001225208-17-014467 · doc4.xml · nonDerivative · entry 7 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,233 F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $27.45 to $27.465, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 10,000 | $7.39 | $73,900.00 |
DisclosureSEC source: 0001225208-17-014467 · doc4.xml · nonDerivative · entry 6 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 20,000 | $7.41 | $148,200.00 |
DisclosureSEC source: 0001225208-17-014467 · doc4.xml · nonDerivative · entry 5 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,031 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001225208-17-014467 · doc4.xml · derivative · entry 10 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,031 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001225208-17-014467 · doc4.xml · derivative · entry 9 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,231 Underlying: Common Stock · 10,000 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase 48,231 shares of common stock vesting in four annual increments beginning on February 16, 2011, the first anniversary of the grant. Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $12.52 | $0.00 |
DisclosureSEC source: 0001225208-17-014467 · doc4.xml · derivative · entry 8 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,568 Underlying: Common Stock · 10,000 shares Expires 2018-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase 25,568 shares of common stock vesting in four annual increments beginning on February 12, 2009, the first anniversary of the grant. Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 27,031 | $27.08 | $732,083.28 |
DisclosureSEC source: 0001225208-17-014467 · doc4.xml · nonDerivative · entry 4 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,233 F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at $27.08 and $27.09. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 7,031 | $6.28 | $44,154.68 |
DisclosureSEC source: 0001225208-17-014467 · doc4.xml · nonDerivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 10,000 | $7.41 | $74,100.00 |
DisclosureSEC source: 0001225208-17-014467 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 10,000 | $12.52 | $125,200.00 |
DisclosureSEC source: 0001225208-17-014467 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 01:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 26,350 | $0.00 Strike: $24.55 | $0.00 |
DisclosureSEC source: 0001225208-17-005156 · doc4.xml · derivative · entry 7 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,350 Underlying: Common Stock · 26,350 shares Expires 2027-02-28 F8 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 01:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 10,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005156 · doc4.xml · derivative · entry 6 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,750 Underlying: Common Stock · 10,750 shares Expires 2018-12-31 F6 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock F7 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F7 · derivative.exercise_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F7 · derivative.expiration_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F7 · balance_after: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 01:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 8,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005156 · doc4.xml · derivative · entry 5 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,146 Underlying: Common Stock · 8,146 shares Expires 2022-02-28 F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 01:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 3,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005156 · doc4.xml · derivative · entry 4 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,383 Underlying: Common Stock · 3,383 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 01:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 12,832 | $24.55 | $315,025.60 |
DisclosureSEC source: 0001225208-17-005156 · doc4.xml · nonDerivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,091 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.